Early Flu Antiviral Use Reduces Hospitalizations

A study published in the International Journal of Infectious Diseases found early administration of Oseltamivir (Tamiflu) has a beneficial impact in reducing 30-day readmissions and mortality in adult influenza patients when compared to a delayed administration after hospital admission or untreated patients and should be considered in all patients who require hospitalisation.

These Australian researchers concluded by saying 'The beneficial effect of Oseltamivir in reducing readmissions could be related to a reduction in the incidence of secondary complications of influenza such as bacterial pneumonia or fewer exacerbations of underlying chronic medical conditions.'

'The findings of this study support the Infectious Diseases Society of America clinical practice guidelines on influenza and the US Centers for Disease Control and Prevention (CDC) antiviral treatment recommendations for influenza (Nov. 30, 2020) that clinicians should start antiviral treatment as soon as possible for hospitalized patients with documented or suspected influenza regardless of illness duration prior to hospitalization.'

The CDC states 'Decisions about starting antiviral treatment for patients with suspected influenza should not wait for laboratory confirmation of influenza virus infection. Empiric antiviral treatment should be started as soon as possible in the priority groups.'